Clinical Trial Update: Relapse-prevention Study With Lu AA21004 (Vortioxetine) in Patients With Generalized Anxiety Disorder [Phase 3]

View source ↗

Summary

Phase 3 relapse-prevention study of vortioxetine (Lu AA21004) in generalized anxiety disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• Lu AA21004 (Vortioxetine) (vortioxetine)

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Generalized Anxiety Disorder | Phase 3 | Status: COMPLETED